Philip J. Barter

Effect of high-density lipoproteins on the expression of adhesion molecules in endothelial cells.

Coronary plaque regression: role of low density lipoprotein-apheresis.

Evidence that phospholipids play a key role in pre-beta apoA-I formation and high-density lipoprotein remodeling.

Metabolism of apoA-I as lipid-free protein or as component of discoidal and spherical reconstituted HDLs: studies in wild-type and hepatic lipase transgenic rabbits.

Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis.

Apolipoprotein A-II inhibits high density lipoprotein remodeling and lipid-poor apolipoprotein A-I formation.

Formation and metabolism of prebeta-migrating, lipid-poor apolipoprotein A-I.

Evidence that hepatic lipase and endothelial lipase have different substrate specificities for high-density lipoprotein phospholipids.

Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study.

High-density lipoproteins neutralize C-reactive protein proinflammatory activity.

Apolipoprotein E enhances hepatic lipase-mediated hydrolysis of reconstituted high-density lipoprotein phospholipid and triacylglycerol in an isoform-dependent manner.

Antiinflammatory properties of HDL.

Relation between atherogenic dyslipidemia and the Adult Treatment Program-III definition of metabolic syndrome (Genetic Epidemiology of Metabolic Syndrome Project).

Reconstituted high-density lipoproteins inhibit the acute pro-oxidant and proinflammatory vascular changes induced by a periarterial collar in normocholesterolemic rabbits.

High-density lipoproteins as therapeutic targets.

Multiple QTLs influencing triglyceride and HDL and total cholesterol levels identified in families with atherogenic dyslipidemia.

Impact of short-term administration of high-density lipoproteins and atorvastatin on atherosclerosis in rabbits.

Formation of high density lipoproteins containing both apolipoprotein A-I and A-II in the rabbit.

Regulation of reconstituted high density lipoprotein structure and remodeling by apolipoprotein E.

Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease.

High-density lipoproteins enhance progenitor-mediated endothelium repair in mice.

Cardioprotective properties of fibrates: which fibrate, which patients, what mechanism?

Relationship between the concentration and antiatherogenic activity of high-density lipoproteins.

Consumption of saturated fat impairs the anti-inflammatory properties of high-density lipoproteins and endothelial function.

Homocysteine and cardiovascular disease: is HDL the link?

Is it appropriate to make statins available over the counter? The argument against the appropriateness of over-the-counter statins.

Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia.

N-Glycosylation regulates endothelial lipase-mediated phospholipid hydrolysis in apoE- and apoA-I-containing high density lipoproteins.

Low dose apolipoprotein A-I rescues carotid arteries from inflammation in vivo.

Is there a role for fibrates in the management of dyslipidemia in the metabolic syndrome?

Identification and characterization of two non-secreted PCSK9 mutants associated with familial hypercholesterolemia in cohorts from New Zealand and South Africa.

Remodeling of apolipoprotein E-containing spherical reconstituted high density lipoproteins by phospholipid transfer protein.

Effects of torcetrapib in patients at high risk for coronary events.

New insights into the role of HDL as an anti-inflammatory agent in the prevention of cardiovascular disease.

Plasma PCSK9 concentrations correlate with LDL and total cholesterol in diabetic patients and are decreased by fenofibrate treatment.

Antiinflammatory actions of HDL: a new insight.

The metabolism and anti-atherogenic properties of HDL.

Acute hypertriglyceridaemia in humans increases the triglyceride content and decreases the anti-inflammatory capacity of high density lipoproteins.

Genome-wide linkage and association analyses to identify genes influencing adiponectin levels: the GEMS Study.

Relationships of HDL cholesterol, ApoA-I, and ApoA-II with homocysteine and creatinine in patients with type 2 diabetes treated with fenofibrate.

Cholesterol metabolism and pancreatic beta-cell function.

Reconstituted high-density lipoprotein suppresses leukocyte NADPH oxidase activation by disrupting lipid rafts.

Genetic association and interaction analysis of USF1 and APOA5 on lipid levels and atherosclerosis.

Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER Database.

The 5A apolipoprotein A-I mimetic peptide displays antiinflammatory and antioxidant properties in vivo and in vitro.

Meta-analysis of comparative efficacy of increasing dose of Atorvastatin versus Rosuvastatin versus Simvastatin on lowering levels of atherogenic lipids (from VOYAGER).

Nonenzymatic glycation impairs the antiinflammatory properties of apolipoprotein A-I.

Evidence that niacin inhibits acute vascular inflammation and improves endothelial dysfunction independent of changes in plasma lipids.

Effects of high-density lipoproteins on pancreatic beta-cell insulin secretion.

Anti-inflammatory effects of apolipoprotein A-I in the rabbit.

High-density lipoproteins suppress chemokines and chemokine receptors in vitro and in vivo.

The relationship between cholesteryl ester transfer protein and cardiovascular risk.

Lipid-free apolipoprotein A-I and discoidal reconstituted high-density lipoproteins differentially inhibit glucose-induced oxidative stress in human macrophages.

Inhibition of rupture of established atherosclerotic plaques by treatment with apolipoprotein A-I.

The apolipoprotein A-I mimetic peptide ETC-642 exhibits anti-inflammatory properties that are comparable to high density lipoproteins.

The causes and consequences of low levels of high density lipoproteins in patients with diabetes.

Effect of torcetrapib on glucose, insulin, and hemoglobin A1c in subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial.

Association of lower total bilirubin level with statin usage: the United States National Health and Nutrition Examination Survey 1999-2008.

Predictive value of different HDL particles for the protection against or risk of coronary heart disease.

Effect of two intensive statin regimens on progression of coronary disease.

Niacin inhibits vascular inflammation via the induction of heme oxygenase-1.

The apolipoprotein A-I mimetic peptide, ETC-642, reduces chronic vascular inflammation in the rabbit.

ApoA-I induction as a potential cardioprotective strategy: rationale for the SUSTAIN and ASSURE studies.

The inhibition of cholesteryl ester transfer protein: a long and winding road.

Cholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk.

Plasma PCSK9 levels and clinical outcomes in the TNT (Treating to New Targets) trial: a nested case-control study.

Relationship between atorvastatin dose and the harm caused by torcetrapib.

High-density lipoproteins inhibit vascular endothelial inflammation by increasing 3β-hydroxysteroid-Δ24 reductase expression and inducing heme oxygenase-1.

Effects of dalcetrapib in patients with a recent acute coronary syndrome.

Long-term fenofibrate therapy increases fibroblast growth factor 21 and retinol-binding protein 4 in subjects with type 2 diabetes.

Arthritis: its prevalence, risk factors, and association with cardiovascular diseases in the United States, 1999 to 2008.

Dalcetrapib in patients with an acute coronary syndrome.

The conundrum of C-reactive protein as a risk marker for cardiovascular risk assessment: insight from EPIC-Norfolk and JUPITER.

Achievement of 2011 European low-density lipoprotein cholesterol (LDL-C) goals of either <70 mg/dl or ≥ 50% reduction in high-risk patients: results from VOYAGER.

Achievement of LDL-C goals depends on baseline LDL-C and choice and dose of statin: an analysis from the VOYAGER database.

Trends in C-reactive protein levels in US adults from 1999 to 2010.

Cardioprotective functions of HDLs.

High-density lipoproteins: a consensus statement from the National Lipid Association.

High density lipoproteins improve insulin sensitivity in high-fat diet-fed mice by suppressing hepatic inflammation.

Inhibition of arthritis in the Lewis rat by apolipoprotein A-I and reconstituted high-density lipoproteins.

Regulation of high-density lipoprotein metabolism.

High density lipoprotein: a therapeutic target in type 2 diabetes.

HDL-transferred microRNA-223 regulates ICAM-1 expression in endothelial cells.

Elevated plasma PCSK9 level is equally detrimental for patients with nonfamilial hypercholesterolemia and heterozygous familial hypercholesterolemia, irrespective of low-density lipoprotein receptor defects.

Cardiovascular drugs that increase the risk of new-onset diabetes.

Effect of change in body weight on incident diabetes mellitus in patients with stable coronary artery disease treated with atorvastatin (from the treating to new targets study).

The relationship between total bilirubin levels and total mortality in older adults: the United States National Health and Nutrition Examination Survey (NHANES) 1999-2004.

The relationship between insulin resistance and vascular calcification in coronary arteries, and the thoracic and abdominal aorta: the Multi-Ethnic Study of Atherosclerosis.

Apolipoprotein A-I increases insulin secretion and production from pancreatic β-cells via a G-protein-cAMP-PKA-FoxO1-dependent mechanism.

Antiatherosclerotic effects of long-term maximally intensive statin therapy after acute coronary syndrome: insights from Study of Coronary Atheroma by Intravascular Ultrasound: Effect of Rosuvastatin Versus Atorvastatin.

The relationship of fibroblast growth factor 21 with cardiovascular outcome events in the Fenofibrate Intervention and Event Lowering in Diabetes study.

Cholesteryl ester transfer protein inhibition enhances endothelial repair and improves endothelial function in the rabbit.

Relationship of pericardial fat with biomarkers of inflammation and hemostasis, and cardiovascular disease: the Multi-Ethnic Study of Atherosclerosis.

Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial.

Relationship of fibroblast growth factor 21 with baseline and new on-study microvascular disease in the Fenofibrate Intervention and Event Lowering in Diabetes study.

To what extent do high-intensity statins reduce low-density lipoprotein cholesterol in each of the four statin benefit groups identified by the 2013 American College of Cardiology/American Heart Association guidelines? A VOYAGER meta-analysis.

Relationship of pericardial fat with lipoprotein distribution: The Multi-Ethnic study of atherosclerosis.

Increasing HDL levels by inhibiting cholesteryl ester transfer protein activity in rabbits with hindlimb ischemia is associated with increased angiogenesis.

Is Cholesteryl Ester Transfer Protein Inhibition an Effective Strategy to Reduce Cardiovascular Risk? CETP Inhibition as a Strategy to Reduce Cardiovascular Risk: The Pro Case.

Doses of rosuvastatin, atorvastatin and simvastatin that induce equal reductions in LDL-C and non-HDL-C: Results from the VOYAGER meta-analysis.

Apolipoprotein A-I Limits the Negative Effect of Tumor Necrosis Factor on Lymphangiogenesis.

Reduction in PCSK9 levels induced by anacetrapib: an off-target effect?

Effect of the BET Protein Inhibitor, RVX-208, on Progression of Coronary Atherosclerosis: Results of the Phase 2b, Randomized, Double-Blind, Multicenter, ASSURE Trial.

Speed kills in more ways than one: Methamphetamine and atherosclerosis.

Targeting High-density Lipoproteins to Reduce Cardiovascular Risk: What Is the Evidence?

Apolipoprotein A-I interactions with insulin secretion and production.

Assessment of the clinical effects of cholesteryl ester transfer protein inhibition with evacetrapib in patients at high-risk for vascular outcomes: Rationale and design of the ACCELERATE trial.

Cholesteryl Ester Transfer Protein Inhibition Is Not Yet Dead--Pro.

A novel class of copper(II)- and zinc(II)-bound non-steroidal anti-inflammatory drugs that inhibits acute inflammation in vivo.

High-Density Lipoprotein-Associated miR-223 Is Altered after Diet-Induced Weight Loss in Overweight and Obese Males.

Inhibition of inflammatory signaling pathways in 3T3-L1 adipocytes by apolipoprotein A-I.

A VOYAGER Meta-Analysis of the Impact of Statin Therapy on Low-Density Lipoprotein Cholesterol and Triglyceride Levels in Patients With Hypertriglyceridemia.

New Era of Lipid-Lowering Drugs.

Coronary artery disease: Scavenger receptor class B1--a target to reduce CHD risk?

In vivo PET imaging with [(18)F]FDG to explain improved glucose uptake in an apolipoprotein A-I treated mouse model of diabetes.

Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel.

Variability of low-density lipoprotein cholesterol response with different doses of atorvastatin, rosuvastatin, and simvastatin: results from VOYAGER.

Impact of Perturbed Pancreatic β-Cell Cholesterol Homeostasis on Adipose Tissue and Skeletal Muscle Metabolism.

Treatment With Dalcetrapib Modifies the Relationship Between High-Density Lipoprotein Cholesterol and C-Reactive Protein.

Erratum. Impact of Perturbed Pancreatic β-Cell Cholesterol Homeostasis on Adipose Tissue and Skeletal Muscle Metabolism. Diabetes 2016;65:3610-3620.

Aldosterone Does Not Predict Cardiovascular Events Following Acute Coronary Syndrome in Patients Initially Without Heart Failure.

The ATP binding cassette transporter, ABCG1, localizes to cortical actin filaments.